Dr. Mark P. Schoenberg is a renowned urologist and executive leader serving as Chief Medical Officer at UroGen Pharma Ltd., a biopharmaceutical company focused on urologic oncology. He earned his medical degree from the University of Pennsylvania School of Medicine and completed his urology residency and fellowship in urologic oncology at The Johns Hopkins Hospital. Dr. Schoenberg has held prominent academic and clinical positions, including Chairman of Urology at Montefiore Medical Center and the Miriam and Benedict Wolf Professor of Urology at Albert Einstein College of Medicine. Prior to joining UroGen, he served as Executive Vice President and Chief Medical Officer at BC Platforms, Senior Vice President of Medical Affairs at EMD Serono, and in leadership roles at Eisai and other organizations. A pioneer in robotic surgery and minimally invasive techniques for bladder cancer, Dr. Schoenberg has authored over 200 peer-reviewed publications, numerous book chapters, and edited leading textbooks in urologic oncology. He has been a principal investigator in pivotal clinical trials and held influential roles in professional societies, including President of the Society of University Urologists, Chairman of the American Urological Association's Oncology Guidelines Committee, and a director on the American Board of Urology. At UroGen Pharma, Dr. Schoenberg leads the medical strategy, clinical development, and regulatory efforts for innovative therapies targeting urothelial cancers, including Jelmyto® (mitomycin for pyelocalyceal solution), the first FDA-approved drug for low-grade upper tract urothelial cancer, and the investigational UGN-102 for low-grade intermediate-risk non-muscle invasive bladder cancer. His expertise drives UroGen's mission to transform patient outcomes through targeted, sustained-release treatments that minimize surgical interventions.